成人及儿童表皮坏死松解症发病率、病因与预后比较:法国人群研究
基于法国健康系统数据库2013—2022年数据,纳入1440例表皮坏死松解症住院患者(儿童219例、成人1221例),比较两组发病率、可疑致病药物暴露及院内死亡。儿童发病率1.5例/百万 person-years,低于成人2.6例;儿童暴露可疑药物比例42.5%低于成人67.9%(调整OR 0.43);儿童院内死亡率1.4%低于成人19.4%(调整HR 0.12)。
要点
- 儿童表皮坏死松解症发病率低于成人(1.5 vs 2.6例/百万 person-years)。
- 儿童病前可疑药物暴露比例低于成人(42.5% vs 67.9%,调整OR 0.43)。
- 儿童院内死亡率显著低于成人(1.4% vs 19.4%,调整HR 0.12)。
核心结论
- 儿童表皮坏死松解症较成人更罕见、更少由药物引起且预后更好。
- 结果提示成人与儿童表皮坏死松解症可能存在不同病理生理机制与临床特点。
研究设计与样本
- 基于法国健康系统数据库2013年1月1日至2022年12月31日数据的人群研究。
- 采用ICD-10编码联合验证算法识别住院表皮坏死松解症患者,共纳入1440例(儿童219例、成人1221例)。
- 采用多因素logistic回归估计儿童与可疑药物暴露的关联,采用多因素Cox比例风险模型估计与院内死亡的关联。
主要发现
- 儿童表皮坏死松解症发病率为1.5例/百万 person-years(95%CI 1.3-1.7),成人为2.6例/百万 person-years(95%CI 2.5-2.7)。
- 儿童病前可疑药物暴露比例为42.5%(93/219),成人为67.9%(829/1221),调整OR 0.43(95%CI 0.32-0.59;P<0.001)。
- 儿童院内死亡率为1.4%(95%CI 0.4-3.7),成人为19.4%(95%CI 17.3-21.7),儿童调整HR 0.12(95%CI 0.04-0.38;P<0.001)。
关键数值与推荐
- 可疑药物定义为住院前5至56天内新开具的药物。
- 儿童与成人表皮坏死松解症发病率分别为1.5例/百万 person-years与2.6例/百万 person-years。
- 儿童与成人病前可疑药物暴露比例分别为42.5%与67.9%,调整OR 0.43。
- 儿童与成人院内死亡率分别为1.4%与19.4%,儿童调整HR 0.12。
临床怎么用
- 儿童表皮坏死松解症患者药物归因可能性低于成人,评估病因时需考虑非药物因素。
- 儿童表皮坏死松解症院内死亡风险显著低于成人,但仍需按重症管理。
- 儿童与成人可能存在不同病理生理机制,支持对儿童患者制定针对性诊疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Epidermal necrolysis (EN), comprising Stevens-Johnson syndrome and toxic EN, is a rare and severe blistering reaction, mainly induced by drugs. Differences between paediatric and adult patients regarding incidence, causes and outcomes have been discussed but are based on a limited number of patients from small case series. OBJECTIVES: To directly compare the incidence, cause and prognosis of adult and paediatric EN. METHODS: We used data from the French Health System Database (1 January 2013-31 December 2022). We identified adult and paediatric patients hospitalized for EN using the International Classification of Diseases, 10th Revision codes combined with validated algorithms. Outcomes were the incidence of EN; the presence of a suspected drug before EN onset (defined as a new drug dispensation from 5 to 56 days prehospitalization); and in-hospital mortality. To estimate the association between paediatric EN and the presence of a suspect drug, we computed a multivariable logistic regression with odd ratios (ORs). To estimate the association with mortality, we computed a multivariable Cox proportional hazard ratio (HR) model. RESULTS: A total of 1440 patients [799 (55.5%) female] with EN were included, comprising 219 children and 1221 adults. Among children, the incidence of EN was 1.5 cases [95% confidence interval (CI) 1.3-1.7] per 1 million person-years vs. 2.6 cases (95% CI 2.5-2.7) in adults. Moreover, children had less chance of being given a culprit drug before the onset of EN [n = 93/219 (42.5%) vs. n = 829/1221 (67.9%)], with an adjusted OR of 0.43 (95% CI 0.32-0.59; P < 0.001), together with a better prognosis: the mortality rate in paediatric patients was 1.4% (95% CI 0.4-3.7) vs. 19.4% (95% CI 17.3-21.7) in adults. The adjusted HR for in-hospital mortality in children was 0.12 (95% CI 0.04-0.38; P < 0.001). CONCLUSIONS: Paediatric EN appears to be rarer, with less chance of being caused by drugs and has a better prognosis than adult EN. These results suggest the existence of different underlying pathophysiological mechanisms and clinical particularities between adult and paediatric patients with EN. Epidermal necrolysis (or ‘EN’ for short) is a rare and severe disease. It involves a sudden loss of skin on the body (called ‘epidermal and mucosal detachment’). In most cases, it is caused by a reaction of the immune system to certain medications. However, there can also be cases where the cause is unknown or cannot be determined. Previous research has suggested there could be differences between EN in children and adults, but no direct comparisons have been carried out yet. In this study, we used data from the French health system to look at the records of 1440 patients (219 children and 1221 adults) who had been hospitalized for EN. We found that childhood EN was rarer and was characterized by a lower incidence rate, including being less likely to be caused by medication. Children with EN had a better prognosis, including less chance of dying of EN, than adults. Our study results suggest there could be different mechanisms behind EN in adults and children, and highlights the importance of tailoring care to the needs of children with EN.
引用
- Bettuzzi T, Welfringer-Morin A, Ingen-Housz-Oro S, et al. Comparison of incidence, causes and prognosis of adult and paediatric epidermal necrolysis: a French population-based study. Br J Dermatol. 2024. PMID: 38848542. doi:10.1093/bjd/ljae240
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。